| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depression, Postpartum | 28 | 2022 | 309 | 6.790 |
Why?
|
| Pregnancy Complications | 45 | 2022 | 2806 | 6.610 |
Why?
|
| Depressive Disorder, Major | 51 | 2022 | 4425 | 5.250 |
Why?
|
| Antidepressive Agents | 40 | 2023 | 2813 | 4.070 |
Why?
|
| Psychiatry | 21 | 2021 | 1597 | 3.690 |
Why?
|
| Antipsychotic Agents | 27 | 2023 | 3033 | 3.390 |
Why?
|
| Fatty Acids, Omega-3 | 27 | 2022 | 1267 | 3.330 |
Why?
|
| Abnormalities, Drug-Induced | 9 | 2022 | 312 | 2.620 |
Why?
|
| Mental Disorders | 29 | 2022 | 6395 | 2.440 |
Why?
|
| Women's Health | 16 | 2020 | 1898 | 2.420 |
Why?
|
| Complementary Therapies | 9 | 2013 | 517 | 2.320 |
Why?
|
| Pregnancy | 80 | 2023 | 26832 | 2.150 |
Why?
|
| Ketamine | 8 | 2022 | 441 | 1.760 |
Why?
|
| Serotonin Uptake Inhibitors | 11 | 2022 | 1419 | 1.640 |
Why?
|
| Depressive Disorder | 16 | 2019 | 3811 | 1.560 |
Why?
|
| Perinatal Care | 6 | 2019 | 230 | 1.560 |
Why?
|
| Periodicals as Topic | 6 | 2021 | 1403 | 1.470 |
Why?
|
| Menopause | 9 | 2017 | 1518 | 1.400 |
Why?
|
| Depression | 21 | 2022 | 7202 | 1.330 |
Why?
|
| Reproduction | 4 | 2022 | 639 | 1.310 |
Why?
|
| Bipolar Disorder | 17 | 2022 | 5023 | 1.220 |
Why?
|
| Urea | 5 | 2020 | 441 | 1.220 |
Why?
|
| Valproic Acid | 6 | 2022 | 443 | 1.210 |
Why?
|
| Eicosapentaenoic Acid | 7 | 2019 | 535 | 1.110 |
Why?
|
| Pregnancy Outcome | 7 | 2022 | 2653 | 1.080 |
Why?
|
| Registries | 15 | 2023 | 7989 | 1.080 |
Why?
|
| Career Mobility | 4 | 2012 | 263 | 1.060 |
Why?
|
| Mental Health | 7 | 2021 | 2602 | 1.030 |
Why?
|
| Hot Flashes | 7 | 2020 | 308 | 0.970 |
Why?
|
| Docosahexaenoic Acids | 7 | 2019 | 846 | 0.970 |
Why?
|
| Puerperal Disorders | 4 | 2016 | 277 | 0.960 |
Why?
|
| Psychotropic Drugs | 3 | 2018 | 893 | 0.950 |
Why?
|
| Antimanic Agents | 5 | 2016 | 529 | 0.900 |
Why?
|
| Female | 134 | 2023 | 375205 | 0.880 |
Why?
|
| Mood Disorders | 5 | 2015 | 1100 | 0.880 |
Why?
|
| Psychiatric Status Rating Scales | 19 | 2021 | 6190 | 0.880 |
Why?
|
| Dietary Supplements | 9 | 2022 | 3025 | 0.870 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2018 | 550 | 0.860 |
Why?
|
| Peer Review | 2 | 2014 | 197 | 0.840 |
Why?
|
| Psychotherapy | 7 | 2020 | 1550 | 0.840 |
Why?
|
| Postpartum Period | 8 | 2022 | 970 | 0.830 |
Why?
|
| Humans | 181 | 2023 | 708843 | 0.810 |
Why?
|
| Perimenopause | 4 | 2020 | 131 | 0.810 |
Why?
|
| Anxiety Disorders | 5 | 2018 | 2567 | 0.810 |
Why?
|
| Piperidines | 6 | 2020 | 1582 | 0.800 |
Why?
|
| Central Nervous System Stimulants | 3 | 2020 | 1134 | 0.790 |
Why?
|
| Infertility, Female | 2 | 2018 | 752 | 0.770 |
Why?
|
| Anticonvulsants | 6 | 2022 | 1840 | 0.760 |
Why?
|
| Citalopram | 2 | 2017 | 400 | 0.750 |
Why?
|
| Tetrahydrofolates | 1 | 2019 | 61 | 0.710 |
Why?
|
| S-Adenosylmethionine | 5 | 2013 | 206 | 0.700 |
Why?
|
| Deception | 1 | 2019 | 108 | 0.670 |
Why?
|
| Clinical Trials as Topic | 11 | 2017 | 8024 | 0.660 |
Why?
|
| Fish Oils | 3 | 2011 | 454 | 0.650 |
Why?
|
| Sertraline | 2 | 2009 | 215 | 0.650 |
Why?
|
| Norepinephrine | 1 | 2020 | 912 | 0.650 |
Why?
|
| Benzodiazepines | 4 | 2022 | 1067 | 0.640 |
Why?
|
| Adult | 75 | 2022 | 211041 | 0.640 |
Why?
|
| Sulfides | 1 | 2017 | 167 | 0.620 |
Why?
|
| Estrogens | 3 | 2013 | 1511 | 0.600 |
Why?
|
| Peer Review, Research | 2 | 2009 | 317 | 0.590 |
Why?
|
| Interview, Psychological | 2 | 2017 | 837 | 0.590 |
Why?
|
| Piperazines | 3 | 2017 | 2532 | 0.580 |
Why?
|
| Psychotherapy, Brief | 2 | 2014 | 119 | 0.580 |
Why?
|
| Prenatal Care | 3 | 2019 | 1005 | 0.580 |
Why?
|
| Serotonin | 2 | 2020 | 1034 | 0.580 |
Why?
|
| Drug Labeling | 1 | 2018 | 258 | 0.570 |
Why?
|
| Anxiety | 8 | 2022 | 3887 | 0.570 |
Why?
|
| Double-Blind Method | 22 | 2022 | 11877 | 0.560 |
Why?
|
| Research | 5 | 2018 | 2009 | 0.540 |
Why?
|
| Paroxetine | 3 | 2012 | 172 | 0.540 |
Why?
|
| Hostility | 1 | 2015 | 188 | 0.540 |
Why?
|
| Stress, Psychological | 4 | 2021 | 4176 | 0.540 |
Why?
|
| Treatment Outcome | 41 | 2022 | 61932 | 0.530 |
Why?
|
| Cyclopropanes | 1 | 2016 | 427 | 0.530 |
Why?
|
| Breast Feeding | 5 | 2021 | 1273 | 0.530 |
Why?
|
| Premenopause | 1 | 2019 | 1009 | 0.530 |
Why?
|
| Methylphenidate | 1 | 2018 | 467 | 0.520 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2009 | 509 | 0.520 |
Why?
|
| Lithium | 4 | 2005 | 613 | 0.510 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2018 | 444 | 0.510 |
Why?
|
| Object Attachment | 2 | 2014 | 302 | 0.510 |
Why?
|
| Pregnancy Trimester, First | 5 | 2022 | 825 | 0.500 |
Why?
|
| Postmenopause | 3 | 2020 | 2405 | 0.500 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2020 | 3565 | 0.490 |
Why?
|
| Family Planning Services | 1 | 2016 | 235 | 0.490 |
Why?
|
| Mothers | 4 | 2014 | 1991 | 0.480 |
Why?
|
| Anger | 1 | 2015 | 402 | 0.470 |
Why?
|
| Hypericum | 5 | 2013 | 61 | 0.470 |
Why?
|
| Time Management | 1 | 2012 | 59 | 0.470 |
Why?
|
| Contraception | 1 | 2016 | 311 | 0.470 |
Why?
|
| Phytotherapy | 3 | 2010 | 307 | 0.460 |
Why?
|
| Peripartum Period | 1 | 2013 | 111 | 0.460 |
Why?
|
| Phototherapy | 6 | 2013 | 342 | 0.460 |
Why?
|
| Mother-Child Relations | 2 | 2014 | 493 | 0.460 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 292 | 0.460 |
Why?
|
| Drug Monitoring | 3 | 2015 | 936 | 0.460 |
Why?
|
| Child Rearing | 1 | 2012 | 75 | 0.450 |
Why?
|
| Placebo Effect | 1 | 2017 | 590 | 0.450 |
Why?
|
| Mass Screening | 6 | 2021 | 5182 | 0.450 |
Why?
|
| Pre-Eclampsia | 2 | 2018 | 1108 | 0.440 |
Why?
|
| Aminopyridines | 1 | 2015 | 531 | 0.440 |
Why?
|
| Fatigue | 2 | 2016 | 1450 | 0.440 |
Why?
|
| Women, Working | 1 | 2012 | 82 | 0.440 |
Why?
|
| Patient Selection | 5 | 2017 | 4306 | 0.420 |
Why?
|
| Secondary Prevention | 4 | 2020 | 1505 | 0.420 |
Why?
|
| Capsules | 1 | 2011 | 204 | 0.420 |
Why?
|
| Altruism | 1 | 2013 | 206 | 0.410 |
Why?
|
| Community Mental Health Services | 1 | 2014 | 400 | 0.410 |
Why?
|
| Publishing | 2 | 2019 | 798 | 0.400 |
Why?
|
| Taste | 1 | 2011 | 174 | 0.400 |
Why?
|
| Dysthymic Disorder | 1 | 2010 | 75 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 2927 | 0.390 |
Why?
|
| Mentors | 3 | 2012 | 604 | 0.380 |
Why?
|
| Women | 1 | 2011 | 224 | 0.380 |
Why?
|
| Sex Characteristics | 2 | 2019 | 2510 | 0.380 |
Why?
|
| Biomedical Research | 4 | 2021 | 3266 | 0.380 |
Why?
|
| Cesarean Section | 1 | 2018 | 1306 | 0.370 |
Why?
|
| Gestational Age | 3 | 2016 | 3378 | 0.370 |
Why?
|
| Nortriptyline | 1 | 2009 | 83 | 0.360 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1740 | 0.360 |
Why?
|
| Middle Aged | 44 | 2022 | 213752 | 0.360 |
Why?
|
| Motivation | 1 | 2019 | 1868 | 0.360 |
Why?
|
| Young Adult | 23 | 2022 | 55940 | 0.360 |
Why?
|
| Premature Birth | 2 | 2023 | 1498 | 0.350 |
Why?
|
| Psychotic Disorders | 2 | 2019 | 2800 | 0.350 |
Why?
|
| Lithium Compounds | 2 | 2009 | 235 | 0.350 |
Why?
|
| Acupuncture Therapy | 5 | 2013 | 461 | 0.340 |
Why?
|
| Thiophenes | 1 | 2013 | 597 | 0.340 |
Why?
|
| Perinatology | 1 | 2008 | 54 | 0.340 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 1167 | 0.340 |
Why?
|
| Hospitals, General | 4 | 2022 | 712 | 0.340 |
Why?
|
| Gender Identity | 1 | 2012 | 554 | 0.320 |
Why?
|
| Dibenzothiazepines | 2 | 2007 | 110 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2020 | 11239 | 0.320 |
Why?
|
| Carbamazepine | 4 | 2014 | 223 | 0.320 |
Why?
|
| Child, Hospitalized | 1 | 2009 | 181 | 0.320 |
Why?
|
| Vitamins | 1 | 2015 | 1466 | 0.310 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 316 | 0.310 |
Why?
|
| Risperidone | 3 | 2007 | 375 | 0.310 |
Why?
|
| Reproductive Medicine | 1 | 2008 | 99 | 0.310 |
Why?
|
| Electronic Mail | 1 | 2009 | 235 | 0.310 |
Why?
|
| Drug Therapy, Combination | 12 | 2022 | 6562 | 0.310 |
Why?
|
| Nutrition Assessment | 1 | 2010 | 714 | 0.310 |
Why?
|
| Prospective Studies | 15 | 2023 | 50597 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2016 | 9488 | 0.300 |
Why?
|
| Recurrence | 8 | 2020 | 8255 | 0.300 |
Why?
|
| Physicians, Women | 1 | 2012 | 471 | 0.300 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2008 | 568 | 0.290 |
Why?
|
| Combined Modality Therapy | 7 | 2018 | 8896 | 0.290 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2008 | 710 | 0.290 |
Why?
|
| Faculty | 1 | 2008 | 344 | 0.290 |
Why?
|
| Infant Welfare | 1 | 2005 | 84 | 0.290 |
Why?
|
| Fertilization in Vitro | 1 | 2013 | 1223 | 0.290 |
Why?
|
| Body Mass Index | 3 | 2020 | 12366 | 0.280 |
Why?
|
| Referral and Consultation | 3 | 2014 | 3436 | 0.270 |
Why?
|
| Massachusetts | 7 | 2021 | 8712 | 0.270 |
Why?
|
| Sudden Infant Death | 1 | 2007 | 285 | 0.270 |
Why?
|
| Advisory Committees | 3 | 2019 | 759 | 0.270 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1778 | 0.260 |
Why?
|
| Cognition | 4 | 2017 | 5982 | 0.260 |
Why?
|
| Terminology as Topic | 2 | 2009 | 1620 | 0.260 |
Why?
|
| Postnatal Care | 1 | 2005 | 225 | 0.260 |
Why?
|
| Adolescent | 18 | 2022 | 84718 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1489 | 0.240 |
Why?
|
| Leuprolide | 2 | 2016 | 309 | 0.240 |
Why?
|
| United States | 18 | 2021 | 67165 | 0.240 |
Why?
|
| Premenstrual Syndrome | 2 | 2017 | 108 | 0.240 |
Why?
|
| Leadership | 1 | 2012 | 1325 | 0.240 |
Why?
|
| Vitamin D | 2 | 2022 | 3138 | 0.230 |
Why?
|
| Obstetrics | 1 | 2009 | 620 | 0.230 |
Why?
|
| Placebos | 5 | 2014 | 1733 | 0.230 |
Why?
|
| Biological Psychiatry | 1 | 2022 | 24 | 0.230 |
Why?
|
| Testosterone | 2 | 2004 | 2352 | 0.230 |
Why?
|
| Nasal Sprays | 1 | 2022 | 17 | 0.230 |
Why?
|
| Folic Acid | 4 | 2016 | 1228 | 0.230 |
Why?
|
| Infant, Newborn | 10 | 2023 | 24433 | 0.230 |
Why?
|
| Risk Factors | 16 | 2020 | 69553 | 0.220 |
Why?
|
| Career Choice | 1 | 2008 | 743 | 0.220 |
Why?
|
| Buspirone | 1 | 2022 | 85 | 0.220 |
Why?
|
| Clozapine | 3 | 2003 | 489 | 0.220 |
Why?
|
| Sexual Behavior | 2 | 2009 | 1879 | 0.220 |
Why?
|
| Conflict of Interest | 1 | 2007 | 564 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3153 | 0.210 |
Why?
|
| Disease Progression | 1 | 2018 | 13298 | 0.210 |
Why?
|
| Mental Health Services | 2 | 2020 | 1604 | 0.210 |
Why?
|
| Comorbidity | 7 | 2017 | 10339 | 0.210 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2002 | 167 | 0.210 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2003 | 152 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3275 | 0.210 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2020 | 20 | 0.210 |
Why?
|
| Pandemics | 2 | 2021 | 7089 | 0.210 |
Why?
|
| Tachyphylaxis | 2 | 2018 | 50 | 0.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2022 | 2290 | 0.210 |
Why?
|
| Luteal Phase | 1 | 2021 | 147 | 0.210 |
Why?
|
| Estradiol | 2 | 2020 | 1974 | 0.200 |
Why?
|
| Amines | 2 | 2003 | 292 | 0.200 |
Why?
|
| Male | 34 | 2022 | 349524 | 0.200 |
Why?
|
| Obesity | 2 | 2020 | 12031 | 0.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2014 | 1988 | 0.190 |
Why?
|
| Herbal Medicine | 2 | 2010 | 40 | 0.190 |
Why?
|
| Child Health Services | 1 | 2005 | 678 | 0.190 |
Why?
|
| Sex Factors | 7 | 2013 | 10566 | 0.190 |
Why?
|
| Menarche | 1 | 2002 | 485 | 0.180 |
Why?
|
| Drug Industry | 1 | 2007 | 894 | 0.180 |
Why?
|
| Exercise | 3 | 2014 | 5251 | 0.180 |
Why?
|
| Anniversaries and Special Events | 1 | 2019 | 87 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 149 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 342 | 0.170 |
Why?
|
| Magnetic Field Therapy | 1 | 2017 | 31 | 0.160 |
Why?
|
| Eligibility Determination | 2 | 2019 | 382 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2005 | 1551 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 5045 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 3690 | 0.160 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2017 | 102 | 0.160 |
Why?
|
| Ethinyl Estradiol | 1 | 2017 | 114 | 0.160 |
Why?
|
| Feeding Behavior | 1 | 2010 | 3141 | 0.160 |
Why?
|
| Professional Role | 1 | 2020 | 299 | 0.160 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 963 | 0.160 |
Why?
|
| Triazines | 3 | 2016 | 308 | 0.160 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 325 | 0.160 |
Why?
|
| Androgens | 1 | 2004 | 1216 | 0.150 |
Why?
|
| Texas | 2 | 2014 | 395 | 0.150 |
Why?
|
| Androstenes | 1 | 2017 | 167 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21194 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2014 | 7994 | 0.150 |
Why?
|
| Infant | 7 | 2022 | 34261 | 0.150 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2003 | 1114 | 0.150 |
Why?
|
| Progesterone | 1 | 2020 | 734 | 0.140 |
Why?
|
| Pregnant Women | 2 | 2021 | 479 | 0.140 |
Why?
|
| Lactation | 2 | 2009 | 397 | 0.140 |
Why?
|
| Infusions, Intravenous | 4 | 2022 | 2303 | 0.140 |
Why?
|
| Arizona | 2 | 2005 | 106 | 0.140 |
Why?
|
| Midazolam | 3 | 2022 | 252 | 0.140 |
Why?
|
| Parents | 1 | 2009 | 3154 | 0.140 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 548 | 0.140 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 16008 | 0.140 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 291 | 0.140 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 171 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 3316 | 0.130 |
Why?
|
| Personality Disorders | 2 | 2009 | 704 | 0.130 |
Why?
|
| Weight Gain | 2 | 2020 | 2193 | 0.130 |
Why?
|
| Milk, Human | 2 | 2009 | 464 | 0.130 |
Why?
|
| Exercise Therapy | 4 | 2013 | 901 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 3885 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2014 | 4883 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1521 | 0.130 |
Why?
|
| Patient Care | 1 | 2020 | 610 | 0.130 |
Why?
|
| Benzamides | 1 | 2020 | 1406 | 0.130 |
Why?
|
| Psychological Techniques | 1 | 2013 | 47 | 0.130 |
Why?
|
| Massage | 1 | 2013 | 84 | 0.120 |
Why?
|
| Psychopharmacology | 1 | 2015 | 138 | 0.120 |
Why?
|
| Fertilization | 1 | 2014 | 192 | 0.120 |
Why?
|
| Life Style | 2 | 2008 | 3636 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2009 | 761 | 0.120 |
Why?
|
| Thinking | 1 | 2016 | 315 | 0.120 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2015 | 373 | 0.120 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2012 | 71 | 0.120 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 6879 | 0.120 |
Why?
|
| Schizophrenia | 2 | 2002 | 6663 | 0.120 |
Why?
|
| Bupropion | 1 | 2014 | 290 | 0.120 |
Why?
|
| Affect | 3 | 2020 | 1487 | 0.120 |
Why?
|
| Contraceptives, Oral | 2 | 2007 | 549 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2018 | 23284 | 0.110 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2013 | 195 | 0.110 |
Why?
|
| Interprofessional Relations | 2 | 2009 | 1016 | 0.110 |
Why?
|
| Gravidity | 2 | 2002 | 52 | 0.110 |
Why?
|
| Drug Storage | 1 | 2011 | 54 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 813 | 0.110 |
Why?
|
| Child Care | 1 | 2012 | 116 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 13536 | 0.110 |
Why?
|
| Synaptic Membranes | 1 | 2011 | 87 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2014 | 284 | 0.110 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 611 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 410 | 0.100 |
Why?
|
| Patient Compliance | 2 | 2013 | 2758 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 7487 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 691 | 0.100 |
Why?
|
| Half-Life | 1 | 2011 | 683 | 0.100 |
Why?
|
| Physicians | 1 | 2008 | 4292 | 0.100 |
Why?
|
| Remission Induction | 1 | 2016 | 2399 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2016 | 1188 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2014 | 580 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2015 | 1925 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2010 | 93 | 0.090 |
Why?
|
| 1-Naphthylamine | 1 | 2008 | 51 | 0.090 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2011 | 450 | 0.090 |
Why?
|
| Overweight | 1 | 2020 | 2205 | 0.090 |
Why?
|
| Belgium | 1 | 2008 | 98 | 0.090 |
Why?
|
| Electroconvulsive Therapy | 2 | 2005 | 435 | 0.090 |
Why?
|
| Nutritional Requirements | 1 | 2010 | 289 | 0.090 |
Why?
|
| Parity | 2 | 2002 | 888 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 1073 | 0.090 |
Why?
|
| Journal Impact Factor | 1 | 2009 | 148 | 0.090 |
Why?
|
| Aged | 12 | 2020 | 161488 | 0.080 |
Why?
|
| Work Schedule Tolerance | 1 | 2012 | 560 | 0.080 |
Why?
|
| Cold Temperature | 1 | 2011 | 789 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 600 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2340 | 0.080 |
Why?
|
| Meditation | 1 | 2010 | 231 | 0.080 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 116 | 0.080 |
Why?
|
| Time Factors | 3 | 2016 | 41038 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2011 | 804 | 0.080 |
Why?
|
| Pregnancy, Unplanned | 1 | 2007 | 75 | 0.080 |
Why?
|
| Pharmaceutical Services | 1 | 2008 | 123 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 821 | 0.080 |
Why?
|
| Triglycerides | 1 | 2015 | 2564 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2010 | 1053 | 0.080 |
Why?
|
| Suicide | 2 | 2009 | 1558 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2009 | 438 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 2320 | 0.080 |
Why?
|
| Food Preferences | 1 | 2010 | 375 | 0.080 |
Why?
|
| Health Personnel | 1 | 2020 | 2983 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 318 | 0.080 |
Why?
|
| Birth Weight | 1 | 2014 | 1893 | 0.070 |
Why?
|
| Cholesterol | 1 | 2015 | 2866 | 0.070 |
Why?
|
| Social Environment | 2 | 2008 | 1011 | 0.070 |
Why?
|
| Research Design | 4 | 2013 | 5833 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 224 | 0.070 |
Why?
|
| Maternal Behavior | 1 | 2008 | 300 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2019 | 3776 | 0.070 |
Why?
|
| Tremor | 1 | 2006 | 151 | 0.070 |
Why?
|
| Self Report | 1 | 2017 | 3397 | 0.070 |
Why?
|
| Catecholamines | 1 | 2006 | 391 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2014 | 2524 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2007 | 426 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 456 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2008 | 518 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2011 | 1223 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2008 | 2328 | 0.070 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2004 | 32 | 0.070 |
Why?
|
| Tryptophan | 1 | 2006 | 458 | 0.070 |
Why?
|
| Neurogenesis | 1 | 2011 | 833 | 0.060 |
Why?
|
| Brain | 1 | 2011 | 24969 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1435 | 0.060 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 1161 | 0.060 |
Why?
|
| Libido | 1 | 2004 | 117 | 0.060 |
Why?
|
| Netherlands | 1 | 2008 | 2068 | 0.060 |
Why?
|
| Telemedicine | 1 | 2020 | 2583 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 614 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 2716 | 0.060 |
Why?
|
| Pirenzepine | 1 | 2003 | 117 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 420 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 2565 | 0.060 |
Why?
|
| Lithium Carbonate | 1 | 2003 | 188 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7644 | 0.060 |
Why?
|
| Climacteric | 1 | 2002 | 57 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2022 | 39038 | 0.060 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 328 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2428 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2007 | 722 | 0.060 |
Why?
|
| Folic Acid Deficiency | 1 | 2002 | 109 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2008 | 793 | 0.060 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 1100 | 0.060 |
Why?
|
| Self-Injurious Behavior | 1 | 2007 | 428 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 559 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2009 | 4039 | 0.050 |
Why?
|
| Social Support | 1 | 2011 | 2119 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2008 | 1569 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2008 | 1182 | 0.050 |
Why?
|
| Fructose | 1 | 2003 | 291 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1328 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 2006 | 650 | 0.050 |
Why?
|
| Causality | 1 | 2007 | 1137 | 0.050 |
Why?
|
| Acetates | 2 | 2003 | 307 | 0.050 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 240 | 0.050 |
Why?
|
| Child | 5 | 2022 | 73636 | 0.050 |
Why?
|
| Yoga | 2 | 2014 | 222 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 1406 | 0.050 |
Why?
|
| Prejudice | 1 | 2004 | 570 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2014 | 3956 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2008 | 2837 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2020 | 212 | 0.050 |
Why?
|
| Ovulation | 1 | 2020 | 184 | 0.050 |
Why?
|
| Family Health | 1 | 2004 | 1276 | 0.050 |
Why?
|
| Calcium Channel Blockers | 2 | 2003 | 698 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1662 | 0.040 |
Why?
|
| Zinc | 1 | 2022 | 682 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1588 | 0.040 |
Why?
|
| Body Weight | 1 | 2008 | 4680 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1938 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 1418 | 0.040 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2007 | 1571 | 0.040 |
Why?
|
| Body Image | 1 | 2022 | 598 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 719 | 0.040 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2017 | 100 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 1915 | 0.040 |
Why?
|
| Prevalence | 2 | 2005 | 14712 | 0.040 |
Why?
|
| Diet | 1 | 2015 | 7392 | 0.040 |
Why?
|
| Longevity | 1 | 2004 | 1019 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 895 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2020 | 530 | 0.040 |
Why?
|
| Fertility Agents, Female | 1 | 2016 | 96 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2006 | 2144 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 732 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2005 | 2102 | 0.040 |
Why?
|
| Prognosis | 2 | 2010 | 28919 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3376 | 0.030 |
Why?
|
| Models, Psychological | 1 | 1999 | 823 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 23020 | 0.030 |
Why?
|
| Age of Onset | 1 | 2002 | 3330 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 13274 | 0.030 |
Why?
|
| Random Allocation | 1 | 2019 | 2455 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2015 | 197 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 2000 | 0.030 |
Why?
|
| Genotype | 1 | 2008 | 12863 | 0.030 |
Why?
|
| Caregivers | 1 | 2004 | 1906 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 3934 | 0.030 |
Why?
|
| Acute Disease | 1 | 2002 | 7158 | 0.030 |
Why?
|
| Inflammation | 1 | 2011 | 10019 | 0.030 |
Why?
|
| Decision Making | 1 | 2005 | 3802 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 2713 | 0.030 |
Why?
|
| Linear Models | 1 | 2020 | 5986 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 2017 | 1670 | 0.020 |
Why?
|
| Animals | 2 | 2011 | 170486 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2011 | 23950 | 0.020 |
Why?
|
| Smoking | 1 | 2005 | 8612 | 0.020 |
Why?
|
| Women's Health Services | 1 | 2008 | 93 | 0.020 |
Why?
|
| Glycosides | 1 | 2008 | 99 | 0.020 |
Why?
|
| Quality of Life | 1 | 2008 | 11594 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2502 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 19423 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 920 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 1611 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 4988 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 58184 | 0.020 |
Why?
|
| Indans | 1 | 2003 | 101 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2920 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2876 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2008 | 1134 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 5235 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 1195 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2002 | 39292 | 0.010 |
Why?
|
| Sleep | 1 | 2014 | 4143 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 2046 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6530 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1510 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 9754 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 4293 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 6991 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2006 | 71483 | 0.000 |
Why?
|